ArticleNature cancer2024

Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial.

Stephen J Bagley et al.PubMed ↗Publisher ↗

No numbers read from the abstract.